Florence P A M van Hunsel (Florence van Hunsel, F P A M van Hunsel)

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 34

Top Topics

Loop Mediated Isothermal Amplification

Patient Reported

Rheumatoid Arthritis Patients

Muscle Invasive Bladder Cancer

Top Venues

Pharmacoepidemiology and drug safety

British journal of clinical pharmacology

Expert opinion on drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Leontine van Balveren, Eugène P van Puijenbroek, Linda Davidson, Florence P A M van Hunsel
A case series of bacillus Calmette-Guérin scar reactivation after administration of both mRNA and viral vector COVID-19 vaccines. British journal of clinical pharmacology (2023)
Meiwen van der Boom, Florence P A M van Hunsel
Adverse reactions following MPox (monkeypox) vaccination: an overview from the Dutch and global adverse event reporting systems. British journal of clinical pharmacology (2023)
A Marije Tjeerdsma, Florence P A M van Hunsel, Sonja van de Koppel, Corine Ekhart, Annabella Vitalone, Herman J Woerdenbag
Analysis of Safety Concerns on Herbal Products with Assumed Phytoestrogenic Activity. Pharmaceuticals (Basel, Switzerland) 16 (8) (2023)
Leontine van Balveren, Eugène P van Puijenbroek, Linda Davidson, Florence P A M van Hunsel
A case series of Bacillus Calmette-Guérin scar reactivation after administration of both mRNA and viral vector COVID-19 vaccines. British journal of clinical pharmacology (2023)
Monika Raethke, Florence P A M van Hunsel, Nicolas H Thurin, Caroline Dureau-Pournin, Dirk Mentzer, Barbara Kovačić, Nikica Mirošević Skvrce, Evelien De Clercq, Martine Sabbe, Gianluca Trifirò, Nicoletta Luxi, Alexia Giovanazzi, Saad Shakir, Olaf H Klungel, Sandor Schmikli, Miriam C J M Sturkenboom
Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose. Drug safety (2023)
Meiwen D X van der Boom, Rike van Eekeren, Florence P A M van Hunsel
Observed-over-Expected analysis as additional method for pharmacovigilance signal detection in large-scaled spontaneous adverse event reporting. Pharmacoepidemiology and drug safety (2023)
M D X van der Boom, R van Eekeren, Florence P A M van Hunsel
Observed-over-Expected analysis as additional method for pharmacovigilance signal detection in large-scaled spontaneous adverse event reporting. Pharmacoepidemiology and drug safety (2023)
Moa Gustafsson, Cristiano Matos, João Joaquim, Joep H G Scholl, Florence P A M van Hunsel
Adverse Drug Reactions to Opioids: A Study in a National Pharmacovigilance Database. Drug safety (2023)
C Ouaddouh, Janneke W Duijster, T Lieber, Florence P A M van Hunsel
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands. Expert opinion on drug safety (2023)
P Slingerland, Florence P A M van Hunsel, T Lieber, Leontine van Balveren, Janneke W Duijster
The Effect of Sex on the Incidence, Latency, Duration and Perceived Burden of Adverse Events Following Seasonal Influenza Vaccination in the Netherlands. Drug safety (2023)
Ingrid Oosterhuis, Joep H G Scholl, Eugene P van Puijenbroek, Agnes C Kant, Florence P A M van Hunsel
Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience. Drug safety (2022)
Agnes C Kant, Jurriaan Jansen, Leontine van Balveren, Florence P A M van Hunsel
Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands. Drug safety 45 (4) (2022)
Carolina Valeiro, Cristiano Matos, Joep H G Scholl, Florence P A M van Hunsel
Drug-Induced Sexual Dysfunction: An Analysis of Reports to a National Pharmacovigilance Database. Drug safety 45 (6) (2022)
Corine Rollema, Eric N van Roon, Corine Ekhart, Florence P A M van Hunsel, Tjalling de Vries
Adverse Drug Reactions of Intranasal Corticosteroids in the Netherlands: An Analysis from the Netherlands Pharmacovigilance Center. Drugs - real world outcomes 9 (3) (2022)
Anne-Sophie M W Bekhof, Florence P A M van Hunsel, Sonja van de Koppel, Herman J Woerdenbag
Safety assessment and adverse drug reaction reporting of tea tree oil (Melaleuca aetheroleum). Phytotherapy research : PTR (2022)
Monica van Hoof, Katherine Chinchilla, Linda Härmark, Cristiano Matos, Pedro Inácio, Florence P A M van Hunsel
Factors Contributing to Best Practices for Patient Involvement in Pharmacovigilance in Europe: A Stakeholder Analysis. Drug safety 45 (10) (2022)
Agnes C Kant, Florence P A M van Hunsel
Authors' Reply to Mungmunpuntipantip et al.'s Comment on "Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands". Drug safety 45 (8) (2022)
Florence P A M van Hunsel, Djurre van der Kooi, Sonja van de Koppel, Burt H Kroes, Herman J Woerdenbag
Analysis of Reports on Adverse Drug Reactions Related to Herbal Medicinal Products and Herbal Supplements in the Netherlands Received by the National Pharmacovigilance Centre Lareb. Drug safety 45 (6) (2022)
Lea Lösch, Patrick Brown, Florence P A M van Hunsel
Using structural topic modelling to reveal patterns in reports on opioid drugs in a pharmacovigilance database. Pharmacoepidemiology and drug safety 31 (9) (2022)
Corine Ekhart, Florence P A M van Hunsel, Eugene P van Puijenbroek, Rebecca E Chandler, Eva-Lisa Meldau, Henric Taavola, G Niklas Norén
Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports. Drug safety 45 (2) (2022)
Helen R Gosselt, Elizabeth A Bazelmans, Thomas Lieber, Florence P A M van Hunsel, Linda Härmark
Development of a multivariate prediction model to identify individual case safety reports which require clinical review. Pharmacoepidemiology and drug safety 31 (12) (2022)
Linda Härmark, Gerda Weits, Rietje Meijer, Federica Santoro, G Niklas Norén, Florence P A M van Hunsel
Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands. Drug safety 43 (8) (2021)
Florence P A M van Hunsel, Emma de Jong, Liana Gross-Martirosyan, Jarno Hoekman
Signals from the Dutch national spontaneous reporting system: Characteristics and regulatory actions. Pharmacoepidemiology and drug safety 30 (8) (2021)
Katherine Chinchilla Alfaro, Florence P A M van Hunsel, Corine Ekhart
Persistent sexual dysfunction after SSRI withdrawal: a scoping review and presentation of 86 cases from the Netherlands. Expert opinion on drug safety (2021)
Florence P A M van Hunsel, Laura Peters, Helga Gardarsdottir, Agnes Kant
Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety Signals. Drug safety 44 (5) (2021)
Florence P A M van Hunsel, Corine Ekhart
Unexpected beneficial effects of drugs: an analysis of cases in the Dutch spontaneous reporting system. European journal of clinical pharmacology 77 (10) (2021)
Eline L Giraud, Naomi T Jessurun, Florence P A M van Hunsel, Eugene P van Puijenbroek, Astrid van Tubergen, Peter M Ten Klooster, Harald E Vonkeman
Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients. Expert opinion on drug safety 19 (12) (2020)
Joep H G Scholl, Florence P A M van Hunsel, Eelko Hak, Eugene P van Puijenbroek
Time to onset in statistical signal detection revisited: A follow-up study in long-term onset adverse drug reactions. Pharmacoepidemiology and drug safety 28 (10) (2019)
Florence P A M van Hunsel, Helga Gardarsdottir, Anthonius de Boer, Agnes Kant
Measuring the impact of pharmacovigilance activities, challenging but important. British journal of clinical pharmacology 85 (10) (2019)
Corine Ekhart, Florence P A M van Hunsel, Joep H G Scholl, Sieta T de Vries, Eugene P van Puijenbroek
Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors. Drug safety 41 (7) (2018)
Florence P A M van Hunsel, Sonja van de Koppel, Eugene P van Puijenbroek, Agnes Kant
Vitamin B6 in Health Supplements and Neuropathy: Case Series Assessment of Spontaneously Reported Cases. Drug safety 41 (9) (2018)
Agnes Kant, Florence P A M van Hunsel, Ola Caster, Henric Taavola, Katka Taxis, Eugene P van Puijenbroek
Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a global database. British journal of clinical pharmacology 84 (7) (2018)
Florence P A M van Hunsel, Susan de Waal, Linda Härmark
The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015. Pharmacoepidemiology and drug safety 26 (8) (2017)
Joep H G Scholl, Florence P A M van Hunsel, Eelko Hak, Eugene P van Puijenbroek
A prediction model-based algorithm for computer-assisted database screening of adverse drug reactions in the Netherlands. Pharmacoepidemiology and drug safety 27 (2) (2017)